New WHO recommendations on use of commercial TB IGRAs in low- and middle-income countries

The WHO has published new recommendations related to the use of IGRAs as a replacement of the tuberculin skin test (TST) to detect latent TB in low- and middle-income countries.

The key recommendations are:

  • IGRAs and the TST cannot accurately predict the risk of infected individuals developing active TB;
  • Neither IGRAs nor the TST should be used for the diagnosis of active TB disease;
  • IGRAs are more costly and technically complex to do than the TST. Given comparable performance but increased cost, replacing the TST by IGRAs in resource-constrained settings is not recommended.

Link: WHO Policy Statement on IGRAs